Find Information About:

Drugs & Supplements

Get information and reviews on prescription drugs, over-the-counter medications, vitamins, and supplements. Search by name or medical condition.

Pill Identifier

Pill Identifier

Having trouble identifying your pills?

Enter the shape, color, or imprint of your prescription or OTC drug. Our pill identification tool will display pictures that you can compare to your pill.

Get Started

My Medicine

Save your medicine, check interactions, sign up for FDA alerts, create family profiles and more.

Get Started

WebMD Health Experts and Community

Talk to health experts and other people like you in WebMD's Communities. It's a safe forum where you can create or participate in support groups and discussions about health topics that interest you.

  • Second Opinion

    Second Opinion

    Read expert perspectives on popular health topics.

  • Community


    Connect with people like you, and get expert guidance on living a healthy life.

Got a health question? Get answers provided by leading organizations, doctors, and experts.

Get Answers

Sign up to receive WebMD's award-winning content delivered to your inbox.

Sign Up

Parkinson's Disease Health Center

Font Size

L-Dopa Doesn't Hasten Parkinson's Disease

Study Eases Concerns About Possible Negative Effects of Parkinson's Disease Treatment
WebMD Health News

Dec. 7, 2004 -- A new study helps put to rest worries that the drug L-dopa might speed Parkinson's disease.

L-dopa is the gold standard treatment for Parkinson's disease. It helps reduce many of the disease's most troubling symptoms: trembling, slow motion, rigidity, unstable posture, and frozen gait.

But there's recent experimental laboratory evidence that the helpful drug might kill nerve cells similar to those shown to degenerate in the brain of people with Parkinson's disease -- thus speeding Parkinson's brain degeneration. To test this theory, Columbia University researcher Stanley Fahn, MD, led a study of patients with early Parkinson's disease.

The 361 patients received low, medium, and high doses of L-dopa or inactive placebo pills for 9.5 months. Fahn and colleagues examined them before and after treatment.

"We can assure both patients with early Parkinson's disease and their physicians that, from a clinical perspective, our study did not find that [L-dopa] hastens the progression of Parkinson's disease," the researchers conclude.

Fahn and colleagues report their findings in the Dec. 9 issue of The New England Journal of Medicine.

The researchers also performed brain-function scans on 116 of the patients. They did find that the brain cells of patients taking L-dopa took in less dopamine than untreated patients. In the past, researchers have said that this meant worse Parkinson's disease.

But there was no evidence these patients were getting worse. In fact, those taking the highest L-dopa doses did the best. Fahn and colleagues say their findings question the traditional interpretation of these functional brain scans.

For now, the biggest problem for Parkinson's patients taking L-dopa is finding a dosage that controls their symptoms but limits the drug's side effects.

"Until more evidence is available, we recommend customizing the dose of [L-dopa] to the needs of the individual patient on the basis of the clinical response and the profile of adverse events," Fahn and colleagues write.

Today on WebMD

Parkinsons disease illustration
Causes, symptoms, and treatments.
hands on walker
How does the disease progress?
man with serious expression
8 common questions and answers.
intelligence quotient illustration
What are the advantages of DBS?
Parkinsons Disease Medications
Questions Doctor Parkinsons
Eating Right
Parkinsons Exercise
daughter consoling depressed mother
senior man's hands
Parkinsons Daily